

Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
1	17/SC/0070	215616	Prepare for Kidney Care: a randomised controlled trial of preparing for responsive management versus preparing for renal dialysis in advanced kidney disease	12/11/2018	07/02/2018	06/09/2018	30/05/2017		21/09/2018		16/10/2018	
2	18/YH/0136	214921	A multi-centre, pilot, prospective, trial of DermaRep? Device in the treatment of venous leg ulcers	13/11/2018	20/02/2018	18/09/2018	09/07/2018	24/09/2018	01/10/2018		01/10/2018	
3	18/NW/0408	242862	A phase III, open-label, randomized study to evaluate the efficacy and safety of adjuvant platinum-based chemotherapy in patients with completely resected stage IB (tumors 4cm) to stage IIIa anaplastic lymphoma kinase positive non small cell lung cancer.		20/12/2017	17/08/2018	03/08/2018	05/09/2018	06/09/2018		14/09/2018	Neither
4	18/EE/0176	236637	An open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects =1 and =30 Years of Age With Relapsed/Refractory Precursor B-cell or T- cell Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma		27/11/2017	16/08/2018	16/08/2018	04/09/2018	06/09/2018		06/09/2018	Neither
5	18/LO/0039	232257	Nintedanib as maintenance treatment of malignant pleural mesothelioma (NEMO): a double-blind randomized phase II study of the EORTC Lung Cancer Group	03/09/2018	21/03/2018	03/07/2018	05/02/2018	09/07/2018	25/07/2018		10/08/2018	
6	18/LO/0782	245936	A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN- 90806 Eye Drops, Suspension in Treatment- Na?ve Participants with Neovascular Age- Related Macular Degeneration (AMD)	05/10/2018	11/04/2018	08/08/2018	25/06/2018	14/08/2018	20/08/2018		12/09/2018	
7	17/YH/0228	222492	CALM- 2 ? Controlling and lowering blood pressure with the MobiusHD?	18/03/2019	23/04/2018	22/08/2018	05/10/2017	22/08/2018	04/09/2018		04/09/2018	Neither



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
8	17/LO/1930	235819	A randomized, controlled, open-label, multiple ascending dose study of intravenous brincidofovir in adult allogeneic hematopoietic cell transplant recipients with adenovirus viremia		13/11/2017	22/08/2018	25/01/2018	22/08/2018	24/08/2018		06/09/2018	Neither
9	17/LO/1261	228696	Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients	07/02/2019	29/05/2018	10/08/2018	29/09/2017	20/08/2018	28/08/2018		14/09/2018	Neither
10	18/LO/0656	240062	Multiple escalating dose study of BAY 1093884 in adults with Haemophilia A or B with or without inhibitors	24/07/2018	30/05/2018	16/07/2018	03/07/2018	19/07/2018	20/07/2018		20/07/2018	
11	17/WS/0209	219538	Optimising medication management in children and young people with Attention deficit hyperactivity disorder (ADHD) using an objective measure of attention, impulsivity and activity (QbTest): a feasibility study		31/05/2018	05/07/2018	08/11/2017	10/07/2018	20/07/2018		08/08/2018	Neither
12	18/NW/0326	238314	Metacognitive Therapy for Social Anxiety in Youth: A Systematic Replication Series	10/08/2018	26/06/2018	20/07/2018	22/06/2018	20/07/2018	24/07/2018		24/07/2018	Neither
13	18/NE/0200	244356	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)	28/09/2018	04/07/2018	13/09/2018	27/09/2018	13/09/2018	28/09/2018		28/09/2018	
14	18/NE/0266	241641	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	03/09/2018	28/06/2018	30/07/2018	22/08/2018	30/07/2018	23/08/2018		24/08/2018	
15	18/NW/0412	247770	To evaluate the acceptability (including gastro intestinal tolerance and compliance) of a low calorie peptide based paediatric tube-feed formula for children over 1 year of age	08/08/2018	11/07/2018	26/07/2018	10/07/2018	31/07/2018	03/08/2018		06/08/2018	



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
16	17/LO/0108	221119	MASTER_DAPT - MAnagement of high bleeding risk patients post bioresorbable polymer coated STEnt implantation with an abbReviated versus prolonged DAPT regimen ? MASTER DAPT	06/12/2018	15/06/2018	04/09/2018	10/04/2017	27/09/2018	04/10/2018		11/10/2018	Neither
17	18/SC/0024	219560	Nail bed INJury Analysis (NINJA): Should the nail plate be replaced or discarded after nail bed repair in children?	29/10/2018	10/07/2018	08/08/2018	20/02/2018	17/08/2018	06/09/2018		25/10/2018	Neither
18	18/NW/0253	230484	Feasibility study on the effects of postnatal enalapril on maternal cardiovascular function following early-onset preeclampsia (PICk-UP)	10/09/2018	04/09/2017	13/07/2018	15/06/2018		17/07/2018		05/09/2018	
19	18/NW/0183	240575	An open-label, single-centre, randomised, cross-over design study to assess the efficacy of real-time continuous glucose monitoring in comparison with self-monitoring of blood glucose in young adults and adolescents with type 1 diabetes	15/08/2018	16/11/2017	12/07/2018	02/07/2018		16/07/2018		16/07/2018	
20	16/LO/1318	187932	Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance. (NUC-B)	09/04/2019	16/06/2017	07/09/2018	21/09/2016	24/09/2018	05/10/2018		19/11/2018	Sponsor
21	18/NW/0215	239446	A Phase 2, Randomized, Placebo-Controlled Study Of Safety And Efficacy Following Repeat-Dose Administration Of Evinacumab (Anti-Angptl3) In Patients With Severe Hypertriglyceridemia (Shtg) At Risk For Acute Pancreatitis	09/10/2018	01/08/2017	07/08/2018	20/07/2018	15/08/2018	06/09/2018		17/09/2018	Neither
22	17/WM/0425	232819	A phase III trial evaluating the efficacy and safety of the house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet in children andadolescents (5-17 years) with HDM allergic asthma	25/02/2019	05/12/2017	02/08/2018	15/01/2018	14/09/2018	18/09/2018		11/12/2018	Sponsor
23	18/NW/0169	239423	A Randomised Pilot Study Investigating the Effect of Medium Cut-Off Haemodialysis On Markers of Vascular Health Compared With On-Line Haemodiafiltration	19/09/2018	22/01/2018	20/07/2018	20/06/2018		10/08/2018		10/08/2018	



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
24	18/NW/0052	217378	RUPA	03/01/2019	14/08/2017	24/08/2018	26/04/2018	06/09/2018	06/09/2018		23/11/2018	Sponsor
25	17/NI/0204	230772	Nordic-Baltic-British Study on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)	10/10/2018	09/05/2018	06/09/2018	05/04/2018	27/09/2018	11/09/2018		05/10/2018	
26	18/EE/0005	232671	A Multicenter, Open-Label Study To Estimate The Effect Sizes Of HRCT Endpoints In Response To Glucocorticoid Induction Therapy In Subject With Pulmonary Sarcoidsis		31/01/2018	16/10/2018	19/07/2018	17/10/2018	23/10/2018		17/12/2018	Neither
27	18/NW/0125	224506	RESPECT-PAD:A pilot randomised controlled trial of remotely supervised exercise training for patients with peripheral arterial disease		17/07/2018	17/07/2018	19/08/2018	21/11/2018	21/11/2018		21/11/2018	Sponsor
28	17/NW/0637	229352	BiOmarkers in Urine, anTihypeRtensive trEAtment and blood pressure Control in Hypertensive patients	04/02/2019	22/12/2017	19/11/2018	20/12/2017	13/12/2018	18/12/2018		18/12/2018	Neither
29	18/ES/0101	223790	The Pre-hospital Evaluation of Sensitive Troponin (PRESTO) study	28/02/2019	29/01/2018	11/10/2018	14/09/2018	16/10/2018	16/10/2018		16/10/2018	Neither
30	18/WS/0073	242354	A Randomized, Double-Blind, Placebo Controlled Study To Evaluate Efficacy And Safety Of NEFECON In Patients With Primary IGA Nephropathy At Risk Of Progressing To End-Stage Renal Disease (NeflgArd)	10/01/2019	30/11/2017	05/10/2018	04/06/2018	05/11/2018	06/11/2018		21/11/2018	Neither
31	18/NW/0640	245090	The Functional Outcomes and Stability of Total Knee Replacement Design Concepts	06/02/2019	01/05/2018	07/11/2018	07/11/2018		30/11/2018		30/11/2018	Neither
32	18/EM/0024	232898	A phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults	04/02/2019	14/02/2018	10/10/2018	03/05/2018	10/10/2018	28/11/2018		29/11/2018	Neither

Division of Research & Innovation 4 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
33	18/NE/0169	243977	A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop	11/02/2019	14/05/2018	29/10/2018	04/10/2018	26/11/2018	28/11/2018		02/01/2019	Neither
34	18/NE/0170	246301	A 6-month randomised, double-blind, placebo controlled multicentre parallel group study to evaluate efficacy and safety of bumetanide 0.5mg twice a day followed by an open label active 6-month treatment period with bumetanide (0.5mg twice a day) and a 6 weeks discontinuation period after treatment stop	13/03/2019	14/05/2018	29/10/2018	04/10/2018	26/11/2018	28/11/2018		02/01/2019	Neither
35	18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis Protocol 747-304	25/06/2019	19/04/2018	02/11/2018	13/07/2018	07/12/2018	19/12/2018		20/12/2018	Sponsor
36	18/LO/0755	245151	A Randomized, Open-label, 24-Week Safety, Efficacy, and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age with Short Bowel Syndrome Who are Dependent on Parenteral Support		21/05/2018	01/11/2018	19/06/2018	05/11/2018	17/12/2018		17/12/2018	Neither
37	17/WS/0147	184216	Precision-Panc Master Protocol for patients with pancreatic cancer	08/01/2019	04/06/2018	23/10/2018	05/01/2018	25/11/2018	23/11/2018		06/12/2018	Neither
38	18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission	22/11/2018	20/06/2018	06/11/2018	12/06/2018	16/11/2018	21/11/2018		21/11/2018	

Division of Research & Innovation 5 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
39	18/YH/0264	248535	A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism	26/03/2019	27/07/2018	10/12/2018	24/08/2018	10/12/2018	04/01/2019		05/02/2019	Sponsor
40	18/EM/0193	243749	A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary FocalSegmental Glomerulosclerosis (FSGS)		31/07/2018	14/11/2018	18/09/2018	07/12/2018	11/12/2018		24/12/2018	Neither
41	18/NW/0457	243408	Can smartphone TechnolOGy be used to support an EffecTive Home ExeRcise intervention to prevent falls amongst community dwelling older people?	18/01/2019	13/07/2018	30/11/2018	12/07/2018	20/12/2018	21/12/2018		21/12/2018	
42	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/-Intervention on outcomes in patients with non ST- elevation myocardial infarction	23/01/2019	23/10/2017	28/11/2018	12/09/2018	14/12/2018	20/12/2018		11/01/2019	
43	18/EM/0228	248988	A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult hematopoietic stem cell transplant recipients	08/01/2019	07/08/2018	15/10/2018	21/08/2018	17/10/2018	25/10/2018		05/11/2018	Neither
44	17/EE/0017	213606	Zambon - Promis - A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P.aeruginosa)	02/04/2019	28/05/2018	18/09/2018	24/02/2017	19/10/2018	19/11/2018		27/04/2017	Neither

Division of Research & Innovation 6 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
45	18/LO/0138	238141	Autolus Long Term Follow-Up of Patients Previously Treated With Autologous T Cells Genetically Modified With Retroviral Vectors	06/03/2019	16/08/2018	12/11/2018	18/05/2018	20/12/2018	21/12/2018		25/01/2019	Sponsor
46	18/YH/0017	231431	Improving the safety and continuity of medicines management at care transitions (ISCOMAT): a cluster Randomised Controlled Trial	07/02/2019	10/01/2018	19/11/2018	01/03/2018	28/11/2018	18/12/2018		23/01/2019	Neither
47	18/SC/0432	232642	A Phase 1/2 Open-Label Safety and Dose- Finding Study of BAY 2599023(DTX201), an Adeno Associated Virus (AAV) hu37- Mediated Gene Transfer of B Domain Deleted Human Factor VIII, in Adults with Severe Hemophilia A	18/03/2019	18/09/2018	18/12/2018	24/10/2018	20/12/2018	21/12/2018		02/01/2019	Neither
48	18/EM/0264	231952	CIRRUS-1 is a 12 month, partially-blinded, active-controlled, multicentre, randomized study evaluating efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) of an anti-CD40 monoclonal antibody, CFZ533, in de novo and maintenance kidney transplant recipients	04/02/2019	06/06/2018	19/11/2018	01/11/2018	07/12/2018	11/12/2018		04/01/2019	Neither
49	18/SW/0162	248769	A prospective follow up study to assess performance, safety and efficacy of the PICO 7 NPWT system for surgically closed incision sites and skin grafts	07/12/2018	18/09/2018	09/10/2018	26/07/2018	30/10/2018	06/11/2018		07/11/2018	
50	18/NW/0375	230391	An investigation into the feasibility of incorporating an exercise rehabilitation programme for people with intermittent claudication into an already established Cardiac Rehabilitation service	04/03/2019	04/10/2018	13/12/2018	13/06/2018	13/12/2018	07/01/2019		08/01/2019	Neither
51	18/WA/0154	233884	WHiTE 8 COPAL: A Randomised Controlled Trial of low dose single antibiotic loaded cement versus high dose dual antibiotic loaded cement in patients receiving a hip hemiarthroplasty after fracture.	17/12/2018	26/07/2018	10/10/2018	10/05/2018	11/10/2018	02/11/2018		22/11/2018	

Division of Research & Innovation 7 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
52	17/WM/0316		A Post-Approval Registry of the TREO? Stent- Graft for Patients with Infrarenal Abdominal Aortic Aneurysms	10/06/2019	23/03/2017	26/11/2018	24/10/2017	26/11/2018	29/11/2018		12/12/2018	Neither
53	17/SC/0554	225522	A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy (HATCY study)	24/01/2019	10/02/2018	12/10/2018	23/02/2018	12/10/2018	24/10/2018		02/11/2018	Neither
54	17/WA/0191	228332	Targeted Hypothermia versus Targeted Normothermia after Out-of-hospital Cardiac Arrest. A Randomised Clinical Trial	22/02/2019	12/09/2017	22/11/2018	02/05/2018	12/12/2018	08/01/2019		24/01/2019	Sponsor
55	18/NE/0221	249183	A Phase I, Multicenter, Open-Label, Single- Dose, Dose-Ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6- based Gene Transfer in Subjects with Mucopolysaccharidosis II (MPSII)		30/05/2018	07/12/2018	17/08/2018	14/01/2019	21/01/2019		01/02/2019	Neither
56	18/EM/0166	246673	PULMOCIDE - A double-blind, placebo- controlled study to assess the effects of inhaled PC945 in the treatment of culture- positive Aspergillus fumigatus infection in subjects with moderate to severe asthma	20/02/2019	09/03/2018	19/12/2018	21/08/2018	19/12/2018	20/12/2018		17/01/2019	
57	18/WA/0227	229373	A Prospective study to assess whether the "Tookie Vest for Oncology? reduces central line fall out rate in the paediatric oncology population	11/04/2019	16/11/2017	17/12/2018	17/12/2018		15/01/2019		15/01/2019	Sponsor
58	18/NW/0313	239919	CNTO A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants with Moderate to Severe Crohn?s Disease		11/01/2018	18/10/2018	02/07/2018	18/10/2018	23/10/2018		16/11/2018	Neither

Division of Research & Innovation 8 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
59	17/LO/1727	181571	Second International Inter-Group Study for Classical Hodgkin's Lymphoma in Children and Adolescents	30/04/2019	18/01/2018	12/02/2019	26/02/2018	12/02/2019	21/02/2019		12/03/2019	Neither
60	18/LO/1290	249002	A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV- Negative Recipient (R-) Patients Awaiting Kidney Transplantation from CMV-Positive Donors (D+)		23/04/2018	17/01/2019	06/11/2018	28/01/2019	05/02/2019		22/02/2019	Neither
61	18/LO/0325	229140	Phase 11, open-labelled, multi-centre, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-na?ve children with unresectable or progressive low grade glioma (LGG)		04/05/2018	30/01/2019	26/04/2018	06/03/2019	13/03/2019		26/03/2019	Neither
62	17/YH/0013	213247	A RandomizEd trial of ENtERal Glutamine to minimIZE thermal injury (The RE-ENERGIZE Study)		19/06/2018	28/01/2019	27/04/2018	28/01/2019	19/02/2019		27/02/2019	Neither
63	18/LO/0773	245000	LUSTRUM cross-over cluster randomised controlled trial of Accelerated Partner Therapy (APT) to improve partner notification outcomes for heterosexual people with sexually transmitted Chlamydia trachomatis infection	22/03/2019	27/07/2018	24/01/2019	23/07/2018	21/02/2019	21/02/2019		21/02/2019	
64	18/YH/0223		Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care		19/03/2018	05/02/2019	09/07/2018	02/04/2019	04/04/2019		07/05/2019	Neither
65	18/NE/0078	235552	Multicentre, open label, prospective, single arm study of the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome	18/04/2019	27/07/2018	18/01/2019	13/04/2018	04/02/2019	15/02/2019		20/03/2019	Neither

Division of Research & Innovation 9 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
66	18/LO/1311	248599	A phase III, multicenter, randomized, double-masked, active comparatorcontrolled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (RHINE)	21/05/2019	29/06/2018	06/12/2018	03/10/2018		12/02/2019		12/02/2019	Sponsor
67	18/WM/0143	245749	Smart Matrix - Study Assessing the Safety and Performance of Smart Matrix?Dermal Replacement Scaffold in the Treatment of Full-ThicknessWounds Arising From Surgical Excision of Basal Cell or SquamousCell Carcinomas in Male and Female Adult Patients		26/06/2018	04/01/2019	15/08/2018	24/01/2019	05/02/2019			Sponsor
68	18/EM/0229	250101	A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy		28/05/2018	13/03/2019	04/10/2018	22/03/2019	26/03/2019		01/05/2019	Neither
69	18/LO/1522	249494	A prospective, randomized, double blind, placebo-controlled, multicenter, Phase 3 efficacy and safety study of OTO-104given as a single intratympanic injection in subjects with unilateral Meniere?s disease		21/06/2018	18/02/2019	06/11/2019	18/02/2019	04/04/2019		09/04/2019	Neither
70	18/NW/0710	248241	Chracterisation and targeted TReatment of ACute Exacerbations of Chronic Obstructive Pulmonary Disease. The TRACE-COPD Randomised Controlled Trial.	03/04/2019	19/03/2018	13/03/2019	21/11/2018		22/03/2019		22/03/2019	
71	18/NW/0742	236247	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas	14/05/2019	15/09/2017	27/02/2019	21/02/2019	15/03/2019	21/03/2019		16/04/2019	Neither

Division of Research & Innovation 10 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
72	18/YH/0055	241341	A Phase 2, Prospective, Randomized, Open- label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus- Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant	18/03/2019	09/08/2018	16/01/2019	10/05/2018	24/01/2019	28/01/2019		31/01/2019	
73	18/YH/0322	226765	SUNRRISE - Single Use Negative pRessure dressing for Reduction In Surgical site infection following Emergency laparotomy	19/01/2019	04/10/2018	02/01/2019	10/10/2018	02/01/2019	10/01/2019		15/01/2019	
74	18/WM/0327	252583	WORKWELL: A randomised controlled trial of job retention vocational rehabilitation for employed people with inflammatory arthritis: the WORKWELL trial.	12/03/2019	14/06/2018	21/01/2019	15/11/2018	22/01/2019	05/03/2019		07/03/2019	
75	18/LO/1922	251251	A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants with Sickle Cell Disease		11/07/2018	31/01/2019	09/01/2019	25/02/2019	04/03/2019		27/03/2019	Neither
76	17/SC/0406	217627	The COMET Trial: Concordance between MRI and Pathology in the Diagnosis of Extranodal Tumour Deposits		06/06/2018	14/08/2018	17/10/2017	04/01/2019	04/01/2019			Neither
77	19/NW/0026	249432	VX18-121-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects Aged 18 Years and Older with Cystic Fibrosis	30/04/2019	13/12/2018	19/03/2019	12/03/2019	11/04/2019	12/04/2019		29/04/2019	
78	18/NW/0838	255084	Financial Incentives for Preventing Postpartum return to smoking: the FIPPS feasibility trial	01/04/2019	28/11/2018	17/01/2019	15/01/2019	17/01/2019	06/02/2019		06/02/2019	Neither
79	19/NW/0037	253482	Technical development of Automated Low Dose Risk Assessment Mammography (ALDRAM) in women attending for annual mammography through a family history clinic	28/03/2019	18/10/2018	05/02/2019	20/02/2019		26/03/2019		26/03/2019	



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
80	18/SS/0131	248427	TOPIC2 - A Randomised Controlled Trial to Investigate the Effectiveness of Thoracic Epidural and Paravertebral Blockade in reducing Chronic Post-Thoracotomy Pain: 2	01/02/2019	17/10/2018	04/12/2018	15/11/2018	11/01/2019	23/01/2019		25/01/2019	
81	18/NW/0585	249119	A data collection and analysis pilot study to indicate preliminary characterisation of the electromyogram signal in relation to needle position with respect to the extraocular muscles, as observed during electromyogram needle guided treatment of strabismus in adults	21/02/2019	17/12/2018	09/01/2019	12/12/2018	17/01/2019	23/01/2019		23/01/2019	
82	18/NI/0240	258468	An Observational, Prospective Multicentre Clinical Study to assess the safety and clinical performance of a New Single-use Negative Pressure Wound Therapy System (PICO 7Y) for the Simultaneous Management of Bilateral Closed Incisions in Oncoplastic Breast Surgery Patients	01/03/2019	16/10/2018	17/01/2019	24/01/2019	14/02/2019	18/02/2019		18/02/2019	
83	18/WM/0204	244427	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation	15/04/2019	18/02/2019	11/03/2019	17/10/2018	12/03/2019	02/04/2019		12/04/2019	
84	18/NW/0098	242717	Two-part, double-blind, placebo-controlled, randomized, parallel-group study: (Part 1) in healthy male subjects to assess safety and tolerability of ascending repeated oral doses of BAY 1902607 including its effect on the pharmacokinetics of a sub-therapeutic dose of midazolam (MDZ), followed by (Part 2) a two-way crossover administration of four different doses of BAY 1902607 in patients with refractory chronic cough to assess safety, tolerability and efficacy for proof of concept	09/04/2019	13/03/2019	13/03/2019	10/05/2018	13/03/2019	13/03/2019		13/03/2019	



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
85	16/EE/0421	209972	A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients with Open-Angle Glaucoma or Ocular Hypertension		16/05/2016	14/01/2019	13/01/2017	14/02/2019	12/02/2019		02/04/2019	Sponsor
86	18/ES/0100	224226	NEST: Clinical Evaluation of Daily Application of Nestorone? (NES) and Testosterone (T) Combination Gel for Male Contraception	14/03/2019	26/05/2016	18/01/2019	07/09/2018	18/01/2019	05/02/2019		06/02/2019	
87	17/SC/0164	210735	CRYOSTAT-2: A multi-centre, randomised, controlled trial evaluating the effects of early high-dose cryoprecipitate in adult patients with major trauma haemorrhage requiring major haemorrhage protocol (MHP) activation	25/04/2019	30/08/2018	11/02/2019	26/05/2017	21/02/2019	22/02/2019		28/02/2019	Neither
88	18/EM/0310	239782	C-Stich2: Emergency Cervical Cerclage to Prevent Miscarriage and Preterm Birth: a Randomised Controlled Trial		03/01/2019	26/03/2019	16/11/2018	04/04/2019	16/04/2019		17/04/2019	Neither
89	18/NW/0325	244842	A Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy		19/01/2018	21/03/2019	30/08/2018	13/05/2019	17/05/2019			Sponsor
90	18/LO/1007	242697	Patient-Reported Outcomes with the Accu- Chek? SoloMicropump System vs. Insulet OmniPod? vs. Multiple DailyInjection Therapy in Type 1 Diabetes		22/11/2017	10/06/2019	14/05/2019	14/06/2019	19/06/2019		19/06/2019	
91	18/LO/0133	228164	Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence?		20/01/2018	15/11/2018	15/03/2018	15/11/2018	12/12/2018		19/12/2018	
92	18/EE/0236	242210	Efficacy and safety of Fixed-Dose Combination (FDC) products containing trazodone andgabapentin in patients affected by painful diabetic neuropathy: randomized, controlled, dosefinding study		31/05/2018	05/12/2018	19/10/2018	03/05/2019	07/05/2019		27/06/2019	Both



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
93	18/NW/0074	236316	Cryoballoon Pulmonary Vein Isolation as First line treatment for Typical Atrial Flutter (CRAFT)	03/05/2019	15/10/2018	31/01/2019	28/02/2018	28/01/2019	31/01/2019		05/02/2019	Neither
94	18/EM/0190	243165	A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel- groupStudy to Investigate the Efficacy and Safety of CSL112in Subjects with Acute Coronary Syndrome		18/04/2018	28/03/2019	14/09/2018	25/04/2019	09/05/2019			Sponsor
95	18/YH/0265	249715	An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism	12/06/2019	03/07/2018	21/05/2019	24/08/2018	31/05/2019	06/06/2019		11/06/2019	
96	17/LO/0812	226255	A Single-arm, Open-label, Multi-centre, Phase 1/II Study Evaluating the Safety and Clinical Activity of AUT03, a CAR T Cell Treatment Targeting CD 19 and CD22 Followed by Consolidation with Anti PO I Antibody in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)	14/05/2019	24/08/2018	16/04/2019	26/07/2017	18/04/2019	03/05/2019		10/05/2019	
97	19/YH/0024	250459	Diagnostic performance of Smart Supra Perimetry (SSP) in comparison with standard automated perimetry (SAP) and ocular coherence tomography (OCT	20/06/2019	29/08/2018	06/06/2019	07/05/2019	11/06/2019	11/06/2019		11/06/2019	
98	18/LO/0797	240879	A Prospective, Multicentre Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma	28/05/2019	03/09/2018	10/04/2019	02/10/2018	10/04/2019	17/04/2019		16/05/2019	
99	17/WA/0192	227541	Targeted therapeutic mild hypercapnia after resuscitated cardiac arrest: A phase III multicentre randomised controlled trial		06/09/2018	23/05/2019	12/11/2018	10/06/2019	17/06/2019		24/06/2019	
100	18/YH/0288	246234	A preliminary study, evaluating and optimizing the clinical workflows to enable a pilot RCT of 3-D printed dentures	03/05/2019	20/09/2018	03/04/2019	10/09/2018	01/05/2019	01/05/2019		01/05/2019	
101	18/EM/0426	236388	OPEN (Novel Outcome measures in PEripheral Nerve Injury)		18/09/2018	16/05/2019	01/03/2019	16/05/2019	23/05/2019		23/05/2019	



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
102	18/EM/0153	240773	A PHASE 3, RANDOMIZED, DOUBLE- BLIND,PLACEBO-CONTROLLED STUDY TO EVALUATE THEEFFICACY AND SAFETY OF AG- 348 IN NOTREGULARLY TRANSFUSED ADULT SUBJECTS WITHPYRUVATE KINASE DEFICIENCY		04/10/2018	29/04/2019	28/08/2018	23/05/2019	11/06/2019			Sponsor
103	18/SW/0218	232727	Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3		23/10/2018	29/05/2019	09/01/2019					
104	18/WM/0022	237623	AN OPEN-LABEL STUDY TO EVALUATE THEEFFICACY AND SAFETY OF AG-348 IN REGULARLYTRANSFUSED ADULT SUBJECTS WITH PYRUVATE KINASE (PK) DEFICIENCY		04/10/2018	03/05/2019	11/04/2018	23/05/2019	11/06/2019			Sponsor
105	17/LO/1819	210698	Image Directed Redesign of Bladder Cancer Treatment Pathways		12/06/2018	13/03/2019	04/12/2017	29/04/2019	17/05/2019			Sponsor
106	19/YH/0050	249236	OpTIMUM: Optimising the Timing of whooping cough Immunisation in MUMs		02/10/2018	10/06/2019	28/03/2019					
107	19/YH/0020	259869	Role of Active Deresuscitation After Resuscitation-2 (RADAR-2): a phase 2 randomised controlled trial.	14/06/2019	03/12/2018	15/03/2019	04/03/2019	01/05/2019	24/05/2019		29/05/2019	Sponsor
108	18/EM/0298	251419	A Phase 3b, Randomized, Double-blind, Placebo-controlledStudy to Evaluate the Efficacy and Safety of TRC101 inDelaying Chronic Kidney Disease Progression in Subjectswith Metabolic Acidosis		11/07/2018	07/05/2019	21/11/2018	15/05/2019	17/05/2019			
109	18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallel-group, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost- effectiveness trial with internal pilot		25/10/2018	03/05/2019	12/11/2018	28/05/2019	11/06/2019			Sponsor

Division of Research & Innovation 15 of 18



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
110	18/NE/0328	238084	An Open label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFN?) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis		21/03/2018	10/06/2019	06/12/2018	11/06/2019				
111	19/LO/0150	258058	A double-blind, placebo controlled, randomized phase III trial to assess the safety and efficacy of Viaskin peanut in peanut-allergic young children 1-3 years of age		26/11/2018	20/05/2019	08/03/2019	24/05/2019	07/06/2019		26/06/2019	
112	18/SC/0395	245499	A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord?, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies	11/06/2019	22/01/2019	07/05/2019	07/01/2019	13/05/2019	14/05/2019		16/05/2019	
113	19/EM/0016	253279	VITALITY (GCA) A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell artheritis		22/01/2019	11/06/2019	15/03/2019					
114	19/SC/0031	257722	A Randomized, Placebo-controlled, Double- blind, Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers 12 to 24 Months of Age		19/12/2018	23/05/2019	10/09/2019	11/06/2019	17/06/2019		18/06/2019	
115	19/EM/0047	257111	A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator- Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration (TENAYA)		05/12/2018	28/05/2019	04/04/2019	25/06/2019	27/06/2019			



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
116	19/NW/0069	246813	Investigation of the oral microbiome in pregnancy - do differences in oral bacterial profiles and nitrate metabolism contribute to blood pressure regulation in pregnant women?	06/06/2019	04/02/2019	26/04/2019	16/04/2019	21/05/2019	21/05/2019		21/05/2019	
117	18/EM/0365	252018	An open-label extension trial of the long- term safety of nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD		23/08/2018	23/05/2019	15/01/2019	23/05/2019	28/05/2019		19/06/2019	
118	19/EE/0091	256412	An open-label, pilot study to assess safety, tolerability, pharmacokinetics and effects of inhaled PC945 in the pre-emptive treatment of Aspergillus fumigatus colonisation in lung transplant recipients		29/11/2018	27/06/2019	20/05/2019					
119	18/SC/0205	245949	An open label phase IV, multicenter, international, interventional study to evaluate the effect of diet on gastrointestinal adverse events in patients with IPF treated with Pirfenidone	23/05/2019	15/01/2019	03/04/2019	23/05/2018	04/04/2019	26/04/2019		29/04/2019	
120	18/NW/0565	246158	A Phase II randomised , double blind, placebo-controlled, parallel group, multicentre study to evaluate the safety and efficacy of repeated oral doses of Blautix in adult subjects with irritable bowel syndrome (IBS) subtypes IBS-C and IBS-D		13/09/2018	08/05/2019	30/01/2019	08/05/2019	10/05/2019		05/06/2019	
121	18/YH/0480	232874	A feasibility Study of Prisms And Therapy In Attention Loss after stroke (SPATIAL feasibility)	25/06/2019	19/10/2018	03/05/2019	09/01/2019	13/05/2019	13/05/2019		13/05/2019	
122	19/LO/0359	253287	An Open-Label, Adaptive Multiple-Dose Study To Investigate The Pharmacokinetics And Pharmacodynamics Of RO7234292 In CSF And Plasma, And Safety And Tolerability Following Intrathecal Administration In Patients With Huntington?s Disease		19/12/2018	24/06/2019	10/06/2019					



Sno	REC Reference	IRAS	Name of Trial	Date of First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non- Confirmation Status	Date Site Ready To Start	Sourceof Reasons for delay
123	18/NE/0023	230930	Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel in the treatment of Irritable Bowel Syndrome with Diarrhoea (IBS-D) in adults		14/03/2018	14/06/2019	27/02/2018					
124	18/LO/2033	252294	When to Induce Labour to Limit risk in pregnancy hypertension ? a multicentre, randomised controlled trial		11/01/2019	21/06/2019	10/01/2019					
125	18/WM/0312	228906	ACCEPTABILITY STUDY ON KETOGENIC DIET SUPPLEMENT USING CAMBROOKE KETOVIE? MEDICAL FOODS	13/02/2019	13/04/2018	29/05/2019	17/12/2018	21/06/2019	24/06/2019		24/06/2019	

Division of Research & Innovation 18 of 18